skip to main content

Ovarian Cancer — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardGynaecological CancersOvarian CancerSCE Medical Oncology

A patient with advanced high-grade ovarian cancer is BRCA wild type but HRD-positive and responds to first-line platinum chemotherapy. She did not receive bevacizumab and remains suitable for maintenance treatment. Which NICE appraisal directly provides a maintenance option?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Rucaparib maintenance under TA1055 for BRCA-wild-type, HRD-positive advanced disease

TA1055 recommends rucaparib after a complete or partial response to first-line platinum treatment for BRCA-negative, HRD-positive advanced high-grade ovarian cancer. Olaparib monotherapy is tied to BRCA-mutated disease, while olaparib-bevacizumab requires response after first-line platinum treatment with bevacizumab. HRD positivity therefore supports rucaparib rather than mandatory observation.

Reference: NICE TA1055 rucaparib after first-line platinum response in advanced ovarian cancer (Published April 2025): https://www.nice.org.uk/guidance/ta1055/chapter/1-Recommendations